Rakuten Medical Closes $119 Million Series E Financing to Further Develop its Alluminox™ Platform [Yahoo! Finance]
HIKMA PHARMS PLC S/ADR (HKMPY)
NASDAQ:AMEX Investor Relations:
hikma.com/en/investors.html
Company Research
Source: Yahoo! Finance
Also supporting development of additional pipeline using the Alluminox™ platform, including ASP-1929 photoimmunotherapy in combination with anti-PD-1, development of new drugs and devices, and further leveraging learnings from real-world experiences in ASP-1929 photoimmunotherapy New investments by Hikma, a global pharmaceutical company, and Mizuho Bank and Dai-ichi Life, leading financial institutions in Japan , as well as additional investments by SBI Group, Rakuten Group and its Chairman and CEO, Mickey Mikitani Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA region joins the board of directors to fuel the next chapter of growth SAN DIEGO March 6, 2024 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced the completion of a $119 million Series E preferred stock financing, including $45 million in new capital a
Show less
Read more
Impact Snapshot
Event Time:
HKMPY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HKMPY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HKMPY alerts
High impacting HIKMA PHARMS PLC S/ADR news events
Weekly update
A roundup of the hottest topics
HKMPY
News
- With 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big guns [Yahoo! Finance]Yahoo! Finance
- Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada [Yahoo! Finance]Yahoo! Finance
- Merck's Bridion faces generic threat from drugmaker Hikma [Reuters]Reuters
- Merck's Bridion faces generic threat from drugmaker Hikma [Yahoo! Finance]Yahoo! Finance
- Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityPR Newswire